Certara, Inc. (NASDAQ:CERT) Receives Average Rating of “Hold” from Analysts

Shares of Certara, Inc. (NASDAQ:CERT) have received an average rating of “Hold” from the thirteen brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $8.85.

Several research analysts recently commented on the stock. KeyCorp reduced their target price on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Monday, April 13th. Morgan Stanley cut their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Barclays reduced their price objective on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Certara in a report on Friday, May 29th. Finally, Craig Hallum lowered their target price on Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research report on Tuesday, May 12th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after buying an additional 2,870 shares during the last quarter. Osaic Holdings Inc. increased its holdings in Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after buying an additional 1,175 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after acquiring an additional 4,930 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Certara in the second quarter valued at $83,000. Finally, Curated Wealth Partners LLC acquired a new stake in Certara in the fourth quarter valued at $89,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Down 4.8%

Shares of Certara stock opened at $6.93 on Friday. The firm has a market cap of $1.08 billion, a PE ratio of -69.30 and a beta of 1.46. The business’s 50 day simple moving average is $5.77 and its 200 day simple moving average is $6.71. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.88 and a current ratio of 1.88. Certara has a 52-week low of $4.45 and a 52-week high of $13.88.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). The business had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.Certara’s revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, analysts predict that Certara will post 0.24 earnings per share for the current fiscal year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.